139 related articles for article (PubMed ID: 23974721)
1. DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells.
Koshio J; Kagamu H; Nozaki K; Saida Y; Tanaka T; Shoji S; Igarashi N; Miura S; Okajima M; Watanabe S; Yoshizawa H; Narita I
Cancer Immunol Immunother; 2013 Oct; 62(10):1619-28. PubMed ID: 23974721
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor.
Miyabayashi T; Kagamu H; Koshio J; Ichikawa K; Baba J; Watanabe S; Tanaka H; Tanaka J; Yoshizawa H; Nakata K; Narita I
Cancer Immunol Immunother; 2011 Nov; 60(11):1597-608. PubMed ID: 21691723
[TBL] [Abstract][Full Text] [Related]
3. DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.
Kim KH; Kang YJ; Jo JO; Ock MS; Moon SH; Suh DS; Yoon MS; Park ES; Jeong N; Eo WK; Kim HY; Cha HJ
Biochem Biophys Res Commun; 2014 May; 447(2):315-22. PubMed ID: 24727449
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
[TBL] [Abstract][Full Text] [Related]
5. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells.
Pietra G; Manzini C; Vitale M; Balsamo M; Ognio E; Boitano M; Queirolo P; Moretta L; Mingari MC
Int Immunol; 2009 Jul; 21(7):793-801. PubMed ID: 19491215
[TBL] [Abstract][Full Text] [Related]
7. Isolation and identification of cancer stem-like cells from murine melanoma cell lines.
Dou J; Pan M; Wen P; Li Y; Tang Q; Chu L; Zhao F; Jiang C; Hu W; Hu K; Gu N
Cell Mol Immunol; 2007 Dec; 4(6):467-72. PubMed ID: 18163959
[TBL] [Abstract][Full Text] [Related]
8. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
[TBL] [Abstract][Full Text] [Related]
9. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
10. Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine.
Zhao F; Zhang R; Wang J; Wu D; Pan M; Li M; Guo M; Dou J
Int Immunopharmacol; 2017 Nov; 52():238-244. PubMed ID: 28950176
[TBL] [Abstract][Full Text] [Related]
11. Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.
Prasad S; Gaedicke S; Machein M; Mittler G; Braun F; Hettich M; Firat E; Klingner K; Schüler J; Wider D; Wäsch RM; Herold-Mende C; Elsässer-Beile U; Niedermann G
Cancer Res; 2015 Jun; 75(11):2166-76. PubMed ID: 25840983
[TBL] [Abstract][Full Text] [Related]
12. Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells.
Jin ZH; Sogawa C; Furukawa T; Saito Y; Aung W; Fujibayashi Y; Saga T
Mol Imaging; 2012; 11(6):445-50. PubMed ID: 23084245
[TBL] [Abstract][Full Text] [Related]
13. [The CD133 polyclonal antibody generation and cancer stem cells identification].
Tian JL; Cai PL; Xia XQ; Li FH; Wang DH; Chen MN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):422-6. PubMed ID: 21827013
[TBL] [Abstract][Full Text] [Related]
14. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
Yang Q; Zhang T; Wang C; Jiao J; Li J; Deng Y
Eur J Pharm Biopharm; 2014 Nov; 88(3):737-45. PubMed ID: 25460146
[TBL] [Abstract][Full Text] [Related]
15. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
16. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties.
Bostad M; Berg K; Høgset A; Skarpen E; Stenmark H; Selbo PK
J Control Release; 2013 Jun; 168(3):317-26. PubMed ID: 23567040
[TBL] [Abstract][Full Text] [Related]
17. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.
Ames E; Canter RJ; Grossenbacher SK; Mac S; Chen M; Smith RC; Hagino T; Perez-Cunningham J; Sckisel GD; Urayama S; Monjazeb AM; Fragoso RC; Sayers TJ; Murphy WJ
J Immunol; 2015 Oct; 195(8):4010-9. PubMed ID: 26363055
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-92 Expression in CD133
Shidal C; Singh NP; Nagarkatti P; Nagarkatti M
Cancer Res; 2019 Jul; 79(14):3622-3635. PubMed ID: 31015227
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI
Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
